Sign In
Buy CYTK
$80.01
+0.84 (+1.06%)
At Close: Jun 23, 2026
Can Cytokinetics (CYTK) Climb 48% to Reach the Level Wall Street Analysts Expect?
11:25am, Wednesday, 27'th Oct 2021
The consensus price target hints at a 47.8% upside potential for Cytokinetics (CYTK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings esti
Cytokinetics to Announce Third Quarter Results on November 3, 2021
04:00pm, Wednesday, 20'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 3, 2021 at 4:0
How Much Upside is Left in Cytokinetics (CYTK)? Wall Street Analysts Think 37%
12:17pm, Monday, 11'th Oct 2021
The average of price targets set by Wall Street analysts indicates a potential upside of 36.8% in Cytokinetics (CYTK). While the effectiveness of this highly sought-after metric is questionable, the p
Go-To-Market Strategy Focuses on Educating Healthcare Professionals, Ensuring Managed Care Access, and Enacting Programs for Patient Access, Education and Support
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:00pm, Friday, 01'st Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 30, 2021 it granted stock options to purchase an aggregate of
Cytokinetics Announces Fourth Annual Communications Fellowship Grant Program Call for Proposals
07:30am, Tuesday, 28'th Sep 2021
Program to Provide $100,000 in Support of Communications and Outreach for Patient Advocacy Organizations Focused on Cardiovascular and Neuromuscular Diseases
Cytokinetics to Host Analyst & Investor Day on October 7, 2021
04:00pm, Thursday, 23'rd Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK), today announced that it will host an Analyst and Investor Day on Thursday, October 7, 2021 fr
Full Results from REDWOOD-HCM Demonstrate Improvements in Biomarkers and Heart Failure Symptoms in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten Supporting Progression
Cytokinetics to Participate in September Investor Conferences
04:00pm, Wednesday, 08'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to pa
Cytokinetics to Host Investor Call and Webcast to Discuss the Full Results From Redwood-HCM at the HFSA Annual Scientific Meeting
07:30am, Tuesday, 07'th Sep 2021
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced it will host a conference call and webcast on September 13, 2021 at 8:30 AM Ea
New Strong Sell Stocks for August 31st
10:40am, Tuesday, 31'st Aug 2021
AMWD, CYTK, STIM, OLLI, and THMO have been added to the Zacks Rank #5 (Strong Sell) List on August 31, 2021.
Full Results from REDWOOD-HCM Expand on Positive Topline Results of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
New Strong Sell Stocks for August 27th
11:32am, Friday, 27'th Aug 2021
CDLX, UUUU, IVC, PSTX, and CYTK have been added to the Zacks Rank #5 (Strong Sell) List on August 27, 2021
Cytokinetics and Cure SMA Renew Partnership to Advance Education and Awareness of SMA
07:30am, Thursday, 19'th Aug 2021
SOUTH SAN FRANCISCO, Calif. and ELK GROVE VILLAGE, Ill., Aug. 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and Cure SMA today announced the renewal of their partnership to in
New Strong Sell Stocks for August 18th
10:45am, Wednesday, 18'th Aug 2021
CYTK, GEVO, ISEE, MCFE, and NOMD have been added to the Zacks Rank #5 (Strong Sell) List on August 18, 2021.
